

Acquisition of own shares

Brussels (Belgium), 27 March 2026 – 20:00 (CET) – Regulated information

In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, UCB SA/NV ("UCB" or the "Company") (Euronext Brussels: UCB) hereby discloses certain information in relation to its Share Repurchase Program 2026.

Under this program, UCB has requested a financial intermediary to repurchase up to 500,000 UCB shares on its behalf under the terms of a discretionary mandate agreement effective as from 16 March 2026 and with initial validity until the later of 30 June 2026, and, to the extent authorized by the extraordinary shareholders' meeting of April 2026, 30 September 2026, to cover current and future obligations under UCB's Long Term Incentive Plans for its personnel.

In the framework of this Share Repurchase Program 2026, UCB repurchased 133,782 UCB shares on Euronext Brussels in the period from 20 March 2026 up to and including 26 March 2026, as follows:


Date of repurchase	Number of shares	Average Price Paid	Total	Lowest Price Paid	Highest Price Paid
20 March 2026	45.632	247,14 €	11.277.533,55 €	243,90 €	254,40 €
23 March 2026	22.032	247,35 €	5.449.524,87 €	239,00 €	251,70 €
24 March 2026	33.782	247,85 €	8.372.743,71 €	247,40 €	251,80 €
25 March 2026	16.413	253,44 €	4.159.659,84 €	249,00 €	256,00 €
26 March 2026	15.923	251,48 €	4.004.316,04 €	250,00 €	253,50 €

This press release is available on UCB SA/NV's website via the following [link](#).

For further information, contact UCB:

Investor Relations
Antje Witte
T +32 2 559 94 14
Antje.Witte@ucb.com

Yvonne Naughton
T: +44-7566790245
yvonne.naughton@ucb.com



UCB News

Sahar Yazdian
T: +32.2.559.9137
sahar.yazdian@ucb.com

Corporate Communications

Laurent Schots
T+32 2 559 92 64
laurent.schots@ucb.com

About UCB

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 9,000 people in approximately 40 countries, the company generated revenue of €7.7 billion in 2025. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB_news.

